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The proton-coupled peptide transporter PEPT2 (SLC15A2)
mediates the high-affinity low-capacity transport of small
peptides as well as various oral peptide-like drugs in the
kidney. In contrast to its well-characterized transport
properties, there is less information available on its
regulatory mechanism, although the interaction of PEPT2 to
the PDZ (PSD-95, DglA, and ZO-1)-domain protein PDZK1 has
been preliminarily reported. To examine whether PDZK1 is a
physiological partner of PEPT2 in kidneys, we started from a
yeast two-hybrid screen of a human kidney cDNA library with
the C-terminus of PEPT2 (PEPT2 C-terminus (PEPT2-CT)) as
bait. We could identify PDZK1 as one of the positive clones.
This interaction requires the PDZ motif of PEPT2-CT detected
by a yeast two-hybrid assay, in vitro binding assay and
co-immunoprecipitation. The binding affinities of second and
third PDZ domains of PDZK1 to PEPT2-CT were measured by
surface plasmon resonance. Co-immunoprecipitation using
human kidney membrane fraction and localization of PEPT2
in renal apical proximal tubules revealed the physiological
meaning of this interaction in kidneys. Furthermore, we
clarified the mechanism of enhanced glycylsarcosine (Gly-Sar)
transport activity in PEPT2-expressing HEK293 cells after the
PDZK1 coexpression. This augmentation was accompanied
by a significant increase in the Vmax of Gly-Sar transport via
PEPT2 and it was also associated with the increased surface
expression level of PEPT2. These results indicate that the
PEPT2–PDZK1 interaction thus plays a physiologically
important role in both oligopeptide handling as well as
peptide-like drug transport in the human kidney.
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Proton-coupled peptide transporters play an important
role in the maintenance of nutrition by mediating the
transport of di- and tripeptides across the brush border
(apical) membranes of the small intestine and kidney. In
addition, peptide transporters function as drug transporters
for peptide-like drugs, including b-lactam antibiotics
and angiotensin converting enzyme inhibitors.1–3 Two
proton-coupled oligopeptide transporters, PEPT1 and
PEPT2, have previously been cloned in rabbits,4–6 rats7–9
and humans.10–12 PEPT1 was thus shown to be a high-
capacity, low-affinity transporter that is expressed mainly
in small intestine and, to smaller extent, in kidneys. It has
been shown to play an essential role in the absorption of
small peptides arising from the digestion of dietary proteins.
In contrast, PEPT2 was found to be a low-capacity, high-
affinity transporter that is expressed in the kidneys. In rats,
Pept1 and Pept2 are sequentially expressed: Pept1 is located
in the early segment and Pept2 is in the late segment of the
proximal tubules.13 In addition, both Pept1 and Pept2 are
localized in the apical membranes of renal proximal tubule in
rats.14,15 Although both transporters are expressed in the
kidney, PEPT2 is thought to play a dominant role in the
conservation of peptide-bound amino acids. Recently, Rubio-
Aliaga et al.16 have reported on the impaired renal
reabsorption of peptide-bound amino acids in animals
lacking Pept2.
Although the transport properties and characteristics of
substrate recognition for PEPT2 have been well documented,
there is less information available on PEPT2 regulation.
Takahashi et al.17 reported a pronounced upregulation of
Pept2 mRNA and protein expression in 5/6 nephrectomized
rats 2 weeks after surgery and the downregulation of its
mRNA 16 weeks after surgery.18 Wenzel et al.19 demonstrated
that the activation of signaling pathways involving protein
kinase C changes the kinetic property of pig Pept2 in a renal
cell line. Recently, Bravo et al.20 demonstrated a strong
inhibitory effect of EGF on the rat Pept2 transport capacity.
However, the modulation of the PEPT2 function by its
associated protein(s) still remains unclear.
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In recent years, several PDZ domain proteins, such as
NHERF1/EBP50, NHERF2/E3KARP, and PDZK1, have been
identified in kidneys and thus have been suggested to be
involved in the stabilization, targeting, and regulation of their
binding partner.21–24 The PDZ (PSD-95, DglA, and ZO-1)-
binding domains have been identified in various proteins and
they are considered to be modular protein–protein recogni-
tion domains that play a role in protein targeting and protein
complex assembly.25–27 This domain binds to proteins
containing the tripeptide motif (S/T)XØ (X¼ any residue
and +¼ a hydrophobic residue) at their C-termini.27 As
Russel et al.28 mentioned, PEPT2 is localized to the apical
membrane and has C-terminal amino-acid sequences that
match the PDZ-binding motif (T-K-L), in a manner similar
to that of other apical organic anion transporters, such as
MRP2/4, NPT1, Oatp1, Oat-k1/k2; thus, indicating that
PEPT2 most likely binds to certain PDZ domain proteins. We
have recently identified that the urate/anion exchanger
URAT1, which has a PDZ motif at its C-terminus (T-Q-F),
interacts with PDZK1.29 Interestingly, both URAT1 and
PEPT2 are expressed at the apical membrane of renal
proximal tubules and they are considered to function in a
reabsorptive pathway for endogenous organic anions (urate30
and oligopeptides,1–3 respectively). It is likely that these
transporters bind to either the same or other PDZ domain
protein(s) via its PDZ-motif.
Very recently, Kato et al.31 examined the interaction
between xenobiotic transporters including PEPT2, and PDZ
proteins including PDZK1. PDZK1, originally identified as a
protein that interacts with MAP17, a membrane-associated
protein,32 has been reported to interact with several
membrane proteins through its PDZ domain.33 Using
coexpression of PEPT2 C-terminus (PEPT2-CT) and PDZK1
in yeast, a possible interaction was demonstrated in the
artificial condition. Because they solely rely on data from in
vitro binding assays and did not provide any evidence that
this interaction truly occurs in proteins expressed from the
endogenous tissue, we performed yeast two-hybrid screening
against a human kidney cDNA library using PEPT2-CT
as bait and thus characterized this interaction in order
to identify PDZK1 as a physiological binding partner of
PEPT2.
RESULTS
Identification of PDZK1 by yeast two-hybrid library screening
In an attempt to isolate PEPT2-interacting protein(s) from
the endogenous genes, we performed yeast two-hybrid
screening against a cDNA library constructed from the
human adult kidney using the PEPT2-CT as bait. From the
8.7 106 transformants screened, we obtained 64 positive
clones. One of these clones had a sequence identical to a
portion of the human PDZK1 gene.32 We could not detect
any interactions between PEPT2-CT and any other PDZ
proteins that are expressed at and/or beneath the apical
membrane of proximal tubules including NHERF1/EBP50,
NHERF2/E3KARP, and IKEPP34–37 (data not shown).
C-terminal PDZ motif of PEPT2 is necessary for PDZK1
interaction
To identify the region of PEPT2 that interacts with PDZK1,
we constructed three mutant baits. A bait (PEPT2-CTd3)
which lacks the last three residues of PEPT2, which play a
crucial role in PDZ domain recognition. Two other baits
(L729A and T727A), the extreme C-terminal leucine (0
position) or threonine (2 position) of PEPT2 was replaced
by alanine, which was expected to abolish the PDZ
interactions.38 These three baits did not interact with PDZK1
(Figure 1a). Therefore, the binding through PEPT2-CT
suggests that the PDZ motif of PEPT2 is the site of
interaction with PDZK1.
The interaction specificity between PDZK1 and PEPT2-
CT was confirmed by a yeast two-hybrid assay using a bait
that had the C-terminus of another human peptide
transporter, PEPT1. PDZK1 did not interact with PEPT1-
CT which lacks a PDZ motif (K-Q-M) (Figure 1b).
Interaction of PDZK1 individual PDZ domains with PEPT2-CT
PDZK1 possesses four PDZ domains which facilitate the
assembly of protein complexes when target proteins bind via
their C-terminal PDZ motifs. To determine the possible
interactions of PEPT2-CT with the PDZ domains of PDZK1,
we produced prey vectors, with each containing one of the
individual PDZ domains (PDZ domain 1 (PDZ1), PDZ2,
PDZ3, and PDZ4) from PDZK1. The interaction with the
C terminal LEU GFP
PEPT2-CTwt I
I
K L E T K K T K L* +
PEPT2-CTd3 K L E T K K * −
PEPT2-L729A I L E T K K T K A* −
PEPT2-T727A I L E T K K A K L* −
+
−
−
−
C terminal LEU GFP
PEPT1-CTwt E  A V T N S Q K Q M* − −
PEPT2-CTwt I  K L E T K K T K L* + +
PDZK1 LEU GFP
PDZ domain 1 −
PDZ domain 2 +
PDZ domain 3 +
PDZ domain 4 −
−
+
+
−
1 2 3 4
N
1
2
3
4
a
b
c C
K
K
Figure 1 | Specificity of PDZK1 interaction with C-termini of
PEPT2 in yeast two-hybrid system. (a) PDZK1 specifically interacted
with the wt PEPT2 C-terminus but not with the C-terminal mutants
L729A, T727A, and d727–729 (d3) of PEPT2. (b) Full-length PDZK1
interacting with the intracellular C-terminus of PEPT2 but not with
that of PEPT1. (c) The wt PEPT2 C-terminus bait interacts with prey
containing either the second or third PDZ domains of PDZK1 (PDZ2,
PDZ3). The specificity of the prey containing a single PDZ domain of
PDZK1 for the PEPT2 bait was confirmed by the absence of growth
associated with the PEPT2 d3 mutant baits. The bars represent the
approximate length of the baits, and the sequence of the last 10
amino acids is shown. pJG4-5 with PDZK1 cDNA expression cassette
is under the control of the GAL1 promoter, such that library proteins
are expressed in the presence of galactose (Gal) but not glucose
(Glu). The system used for the yeast two-hybrid screen includes the
reporter genes LEU2 and GFP, which replace the commonly used
classical lacZ gene and allow a fast and easy detection of positive
clones with long-wave UV. The results from the growth assay and
GFP fluorescence are indicated on the right.
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PEPT2-CT was observed for PDZ2 and PDZ3, but not for
PDZ1 and PDZ4 of PDZK1 (Figure 1c).
In vitro binding of PEPT2 and PDZK1
We used a glutathione-S-transferase (GST) pull-down assay
to confirm the ability of PEPT2-CT to bind to PDZK1
in vitro and validate the protein–protein interaction (Figure
2a). GST fusion proteins bearing the wild-type C-terminus
(PEPT2-CT-wt) or C-terminal mutants (PEPT2-CTd3,
L279A, and T727A) of PEPT2 were used to pull down
in vitro translated full-length PDZK1. The data showed the
same interaction specificity for PDZK1 and PEPT2 as
exhibited in yeast two-hybrid assay (Figure 1a). As expected,
the binding of PDZK1 to PEPT2 was completely abolished
when the C-terminal PDZ motif was removed (PEPT2-
CTd3) or mutated (PEPT2-CT-L729A or PEPT2-CT-T727A)
(Figure 2a).
To confirm and quantify the interaction of PEPT2 with
PDZK1, we performed surface plasmon resonance experi-
ments using immobilized GST-PEPT2-CT and PDZ2 and
PDZ3 of PDZK1 proteins independently fused to maltose-
binding protein. As summarized in Table 1, the binding
affinities of PDZ2 and PDZ3 of PDZK1 are low (KD¼ 10 and
15 mM). These values are low in comparison to most PDZ
domain interactions (KD¼ 1 nM–10 mM).39
Co-immunoprecipitation from heterologous cells and tissue
To demonstrate that PEPT2 and PDZK1 can also interact in
mammalian cells, we used a previously prepared rabbit
polyclonal antibody against PDZK1.29 We coexpressed full-
length human PEPT2 fused with green fluorescent protein
(GFP) (GFP-PEPT2) and PDZK1 in human embryonic
kidney (HEK)293 cells. Wild-type GFP-PEPT2 was co-
immunoprecipitated with a GFP-specific antibody but GFP-
PEPT2 which lacked the last three residues was not
precipitated with PDZK1 (Figure 2b).
Furthermore, we demonstrated an association between
endogenous PDZK1 and PEPT2 in human tissue by co-
immunoprecipitating PEPT2 from human kidney membrane
fractions using the anti-PDZK1 antibody, but not control
immunoglobulin G (Figure 2c). This result is the evidence
that observed interaction occurs between protein partners
expressed from endogenous genes in kidneys.
Expression of PEPT2 in human kidney sections
In rats, Pept2 is present at the apical membrane of renal
proximal tubules14,15 and in humans, PDZK1 is reported to
be expressed at the apical side of proximal tubular cells.29,40
To determine whether PEPT2 and PDZK1 colocalize at the
apical membrane of renal proximal tubules in humans, we
carried out immunostaining of human serial kidney sections
using anti-PEPT2 antibody.41 Consistent with the previous
reports, in the renal cortex, PEPT2 immunoreactivities were
detected at the apical side of proximal tubular cells (Figure 3).
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Figure 2 | Interaction of PDZK1 with PEPT2. (a) Full-length PDZK1
polymerase chain reaction product was in vitro translated in the
presence of Transcend Biotinylated Lysine tRNA (Promega). The in
vitro translation products were incubated with GST alone (lane 1),
GST-PEPT2-CTwt (lane 2), or GST-PEPT2-CTd3 (lane 3) using a
ProFound Pull-Down GST Protein:Protein Interaction kit (Pierce). The
pull-down products were analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. The input corresponds to the
crude in vitro translation reaction. Positions of molecular mass
standards are indicated on the right. GST fused to PEPT2 C-terminal
wt can co-precipitate PDZK1, confirming the specificity found in the
yeast two-hybrid system. The mutant form of PEPT2 in which the
C-terminal PDZ recognition motif is removed is not able to
precipitate PDZK1. (b) Co-immunoprecipitation of PEPT2 and PDZK1
in HEK293 cells. HEK293 cells were transfected with pEGFP-C2
vectors encoding PEPT2-wt (lane 1) or PEPT2-d3 (lane 2) with
pcDNA3.1-PDZK1 and then immunoprecipitated with the anti-GFP
antibody. Then, the immunoprecipitates were resolved by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and probed with
anti-PDZK1 antibodies. (c) Human kidney membrane fractions were
immunoprecipitated with the anti-PEPT2 antibody (lane 1) and
control immunoglobulin G (lane 2). The presence of PDZK1 in the
immunoprecipitates was determined by Western blotting with the
anti-PDZK1 antibody used in a previous study.29
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Figure 3 | Immunohistochemical analysis of PEPT2 in human
kidney sections. (a and b) Immunohistochemical labeling of PEPT2
by diaminobenzidine reaction of human kidney. (a) PEPT2 was
detected in proximal tubules in the cortex. (b) The apical membrane
of proximal tubule was immunostained with the anti-hPET2 antibody
and no immunostaining was observed in the basolateral membrane
and glomeruli. These figures are representative of typical section
samples. Original magnifications, (a)  100 and (b)  400.
Table 1 | Characteristics of interaction between PEPT2
C-terminus and PDZK1 PDZ domains 2 and 3 (PDZ2 and PDZ3)
Construct ka (1/mM s) kd (1/min) KD (lM)
PDZK1-PDZ2 7.2 102 7.5 103 10
PDZK1-PDZ3 3.6 102 5.5 103 15
The kinetic characteristics of the interaction with immobilized GST-fused PEPT2
C-terminus with the second and third PDZ domains of PDZK1 (PDZ2 and PDZ3)
fused with MBP measured by SPR methods are summarized. Association rate
constants (ka), dissociation rate constants (kd), and equilibrium dissociation
constants (KD=kd/ka) are given.
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PEPT2 transport activity increases in presence of PDZK1
To determine whether PEPT2 and PDZK1 interaction is
required to mediate the increase in PEPT2 transport activity,
we transfected HEK293 cells with the pcDNA3.1(þ ) plasmid
containing full-length PEPT2 (HEK-PEPT2-wt), PEPT2
lacking the last three amino acids (HEK-PEPT2-d3), or
without an insert (HEK-mock). The time profile of the
uptake of [14C]glycylsarcosine (Gly-Sar) via PEPT2 is shown
in Figure 4a. Intracellular accumulation of Gly-Sar was linear
within 5 min and it was also significantly greater in HEK-
PEPT2-wt than that in HEK-mock. After 2 min incubation,
we demonstrated that [14C]Gly-Sar uptake via HEK-PEPT2-
wt was approximately 20-fold higher than that in HEK-mock
and that in HEK-PEPT2-d3 was approximately 12-fold
higher than that in HEK mock (Figure 4b). Gly-Sar transport
activities significantly increased after PDZK1 coexpression
(1.5-fold) (Figure 4b). This effect was not observed when
PEPT2-d3 was coexpressed with PDZK1 (Figure 4b).
Next, we examined the effect of PDZK1 coexpression on
the kinetics of [14C]Gly-Sar transport via HEK-PEPT2-wt
that had been transfected with pcDNA3.1-PDZK1 or
pcDNA3.1 alone. Kinetic data showed that PDZK1 signifi-
cantly increased Vmax from 2.92 to 4.95 pmol/mg protein/
min and slightly increased Km from 167 to 189 nM, in
comparison to PEPT2 alone (Figure 4c). Interestingly, the
Vmax of [
14C]Gly-Sar transport via HEK-PEPT2-d3, de-
creased (0.86 pmol/mg protein/min), whereas its Km showed
no change (187 nM).
Surface expression level of PEPT2
To determine changes in the cell surface expression level of
PEPT2, we used a cell-membrane-impermeant biotinylation
reagent to selectively label the cell-surface proteins. After the
treatment, the cell lysates from HEK293 cells transfected with
PEPT2 and PDZK1 or PEPT2 and mock was collected. The
amount of surface-biotinylated PEPT2 expression on plasma
membranes increased 1.8-fold (PEPT2 and mock-transfected:
88.376.9 vs PEPT2 and PDZK1-transfected: 155.5711.3 AU,
n¼ 3) when PDZK1 was coexpressed (Figure 5). This change
seems close to the one in Vmax of PEPT2-mediated transport
observed in Figure 4c.
DISCUSSION
The proton-coupled peptide transporter PEPT2 (SLC15A2)
mediates the high-affinity low-capacity transport of small
peptides in the kidney. Therefore, PEPT2 is presumed to
contribute to the conservation of peptide-bound amino
acids. Although the transport properties and characteristics
of substrate recognition for PEPT2 have been well docu-
mented, there is less information on PEPT2 regulation. A
recent report by Kato et al.31 has provided the novel idea
concerning the modulation of PEPT2 function by its
associated protein. They demonstrated an interaction be-
tween the recombinant PEPT2 C-terminus fused to GST and
purified His-tagged PDZK1, but they solely rely on data from
in vitro binding assays and did not indicate the physiological
importance of this interaction. In addition, the yeast two-
hybrid screens performed by Gisler et al.,42 using baits
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Figure 4 | Effect of PDZK1 on PEPT2-mediated [14C]Gly-Sar
transport activity. (a) The time profile of the uptake of [14C]Gly-Sar
via PEPT2. Intracellular accumulation of Gly-Sar was linear within
5 min and was significantly greater in PEPT2-wt-transfected HEK293
cells (HEK-PEPT2-wt; filled circles) than that in the mock-transfected
cells (HEK-mock; open squares). (b) Coexpression of PEPT2 and
PDZK1 increased [14C]Gly-Sar uptake (30 mM) significantly over cells
transfected with PEPT2 alone (closed column, middle). This effect was
abolished when the C-terminal deletion mutant of PEPT2 was
cotransfected with PDZK1 (HEK-PEPT2-d3; closed column, right),
confirming that the interaction of PDZK1 with PEPT2 C-terminal
domain is responsible for this effect. ***Po0.001 (c) Kinetic data
using PEPT2-expressing HEK293 cells showed that PDZK1 (open
squares) increased the Vmax from 2.92 to 4.95 fmol/mg protein/min
and increased the Km slightly from 167 to 189 mM, as compared with
PEPT2 alone (filled triangles). Vmax of [
14C]Gly-Sar transport via
HEK-PEPT2-d3 decreased (0.86 pmol/mg protein/min), whereas its Km
showed no change (187 nM) (filled circles). The kinetic parameters for
the uptake via PEPT2 were estimated using v¼ Vmax [S]/(Kmþ [S]),
where v is the uptake rate of substrates, [S] is the substrate
concentration (mM) in the medium. Km is the Michaelis–Menten
constant (mM) and Vmax is the maximum uptake rate (pmol/mg of
protein/2 min). These parameters were determined using the
Eadie–Hofstee equation.
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Figure 5 | Surface expression level of PEPT2. (a) cell surface
biotinylation analysis of PEPT2 transiently expressing HEK293 cells
transfected with vector alone (lane 1), and those transfected with
PDZK1 (lane 2). Single bands of approximately 85 kDa, which are
consistent with PEPT2, were observed in both lanes. (b) Quantification
of immunosignal for PEPT2 (n¼ 3, error bars are s.d.). Densitometric
analysis was performed using Model DIANA II Imaging System (M&S
Instruments Trading Inc., Tokyo, Japan). *Po0.05.
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containing single PDZ domains derived from mouse PDZK1,
failed to detect Pept2 as a candidate for PDZK1 binding
although several membrane proteins including Urat1 were
found. To identify PDZK1 as a physiological binding partner
of PEPT2, we evaluated this interaction from several
viewpoints in this study.
Starting from a yeast two-hybrid screening of a human
kidney cDNA library, we have demonstrated PDZK1 to be a
physiological interactor of PEPT2. First, we could detect
PDZK1 from 64 positive clones by library screening. Second,
we could observe the co-immunoprecipitation of PEPT2 and
PDZK1 from kidney membrane fractions (Figure 2c). Third,
we could demonstrate the localization of PEPT2 protein at
the apical side of the renal proximal tubules where PDZK1 is
also expressed (Figure 3). These results indicate the
physiological meaning of this interaction.
We have further examined this interaction by a yeast two-
hybrid assay (Figure 1), an in vitro pull-down assay (Figure
2a), co-immunoprecipitation (Figure 2b) and surface plas-
mon resonance assay (Table 1) of recombinant proteins, as
well as by the transport studies (Figure 4) and a cell surface
biotinylation assay (Figure 5). These results support the
preliminary data presented by Kato et al.31 Moreover, the
augmentation of the transport activity by PDZK1 was
accompanied by a significant increase in the Vmax of Gly-
Sar transport via PEPT2 (Figure 4c) and was associated with
the increased surface expression level of PEPT2 in HEK293
cells (Figure 5). These characteristics are closely similar to
those of the URAT1–PDZK1 interaction,29 and suggest
PDZK1 to thus play a similar role in PEPT2–PDZK1
interaction; namely, that PEPT2 is stabilized and/or anchored
at the cell membrane, making it less likely to be internalized
and subsequently degraded.
Although their functional consequences are the same,
there are several differences between the PEPT2–PDZK1
interaction and the URAT1–PDZK1 interaction. First, the
frequency of PDZK1 appearing as a positive clones was
smaller in the case of PEPT2 (one out of 64) than in the case
of URAT1 (35 out of 98). Second, the interaction profiles of
PDZK1 ligand against individual PDZ domains of PDZK1
were different, although they have similar C-terminal PDZ
motifs: T-K-L for PEPT2 and T-Q-F for URAT1. PEPT2
binds to PDZ2 and PDZ3 (Figure 1), while URAT1 binds to
PDZ1, PDZ2, and PDZ4.29 Third, the binding affinities for
each PDZ domain of PDZK1 were more than 10-fold lower
for PEPT2 than for URAT1: 10 and 15 mM for PEPT2
(Table 1) and 1.97–514 nM for URAT1.29 Fourth, when a C-
terminal deletion mutant of URAT1 (URAT1-d3) was
coexpressed with PDZK1, urate transport activity was not
enhanced, but URAT1-d3 still demonstrated a similar urate
transport activity to wt URAT1 when expressed without
PDZK1. In contrast, the C-terminal deletion mutant of
PEPT2 (PEPT2-d3) not only lacked the ability to enhance
transport activity when coexpressed with PDZK1, but its
transport activity was reduced to half that of the wt PEPT2
(PEPT2-wt) when expressed without PDZK1.
The low frequency of PDZK1 in PEPT2 screening seems
consistent with the report of Gisler et al.42 as we mentioned
earlier in this paper. In addition to the expression levels of
these proteins, the binding affinity is likely to affect the
frequency of a particular protein appearing as a positive clone
in yeast two-hybrid screening. Therefore, a low frequency of
positive clone does not mean that the observed interaction is
physiologically less important. Moreover, a low binding
affinity may be advantageous for the regulatory dynamics of
protein–protein interactions,27 because a low binding affinity
is related to an easier association and dissociation of proteins
than a high binding affinity. In particular, PEPT2 has a
putative protein kinase C (PKC) recognition site at its C-
terminal close to the PDZ motif, whose phosphorylation may
interfere with binding to the PDZ domain.43 It will be
interesting to investigate whether the phosphorylation of
both PEPT2 and PDZK1 or either protein independently
alters the binding affinity of this interaction, in order to
clarify the regulatory mechanism for PDZ–ligand interaction.
The decreased transport activity of the PEPT2 C-terminal
deletion mutant compared to wt PEPT2, together with the
significant reduction in Vmax (Figure 4) may indicate PDZ
motif to thus play another role in the PEPT2-CT: the
targeting of the transporter to the plasma membrane. This
was originally predicted by Russel et al.28 However, as
mentioned above, this phenomenon was not observed in the
C-terminal deletion mutant of URAT1 expressed in the same
HEK293 cells that have endogenous PDZK1 at low level.29
Although we frequently detected PDZK1 in the URAT1
screen, we did not find any other binding candidates for
URAT1. In the PEPT2 screen, we detected several potential
binding partners for PEPT2 besides PDZK1 (manuscript in
preparation). It will therefore be important to identify other
binding proteins surrounding PEPT2 to understand the
potential significance of this interaction.
Recently, PDZ proteins have been recognized as orches-
trating scaffolds to achieve concerted functions.23 PEPT2
mediates an electrogenic proton-coupled cotransport that
uses an inward proton gradient to transport small peptides
from urine to the cell. Following the concept proposed by
Moe, the ability of PDZK1 to couple PEPT2 to the Naþ /Hþ
exchanger NHE3 may provide the necessary lumen-to-cell
proton gradient, and the multimolecular protein complex
will be functionally equivalent to a Naþ /oligopeptide
cotransporter. A functional coupling between PEPT2 and
NHE1 and/or NHE2 has recently been shown by Wada
et al.44 In this paper, we described, for the first time, the exact
localization of PEPT2 in the human kidney in addition to its
novel regulatory mechanism. PEPT2 proteins are expressed at
the apical membrane of renal proximal tubules similarly to
rat Pept1 and rat Pept2, which are expressed in the same
site.15 Based on the above findings, human PEPT2 may
therefore be involved in the reabsorption of peptides on the
apical side of the renal tubules, similar to that of rodent Pept2
and the protein complex surrounding PEPT2 should thus be
clarified by identifying other interacting proteins to obtain a
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comprehensive understanding of the peptide transport
function in the renal proximal tubules.
MATERIALS AND METHODS
Materials
[14C]Glycosylsarcosine (Gly-Sar) (4 Ci/mmol) was obtained from
Moravek (Brea, CA, USA). Other materials used included Ham F12
medium from Nissui Pharmaceutical Co., Ltd. (Tokyo, Japan), and
fetal bovine serum and trypsin from Invitrogen (Carlsbad, CA,
USA).
Cloning of human PEPT2 cDNA
The cDNA library was prepared from human kidney poly(-
A)þRNA.45 The 0.46-kb cDNA fragment (24–481 nt of the
nucleotide sequence of human PEPT2 (hPEPT2)) was obtained by
polymerase chain reaction. This fragment was labeled with
[32P]dCTP (T7QuickPrime, Amersham Biosciences, Tokyo, Japan)
and used as probe. The screening of the cDNA library was
performed as described elsewhere.46
Plasmid construction
The C-terminal fragments of wt hPEPT2 cDNA and three mutants
(designated d3, L729A, and T727A) were generated by polymerase
chain reaction using specific primers (Table 2) and cloned into the
BamHI and XhoI sites of pEG202 (bait) and pGEX-6P-1 (Amersham
Biosciences) to construct PEPT2-CTwt, PEPT2-CTd3, PEPT2-
L729A, and PEPT2-T727A. The full-length coding sequences of
hPEPT2 (wt) as well as its C-terminal 3-amino-acid-deletion
mutant (d3) were inserted into the mammalian expression vector
pcDNA3.1 (Invitrogen) for functional analysis and into pEGFP-C2
(Clontech, Tokyo, Japan) for GFP fusion protein preparation. The
pcDNA3.1 vector containing the full-length human PDZK1
(hPDZK1) and preys (pJG4–5 and pMAL-C2x) containing single
PDZ domains of hPDZK1 were prepared as described previously.29
Yeast two-hybrid assay
A human kidney cDNA library was constructed as described
previously.29 A PEPT2 C-terminal bait corresponding to the last 34
amino acids of PEPT2 was used to screen 8.7 106 clones of the
human kidney cDNA library with the LexA-based GFP two-hybrid
system (Grow‘n’ Glow system; MoBiTec, Go¨ttingen, Germany).
In vitro binding assay
PEPT2-CT for GST fusion protein production in bacteria as
reported previously.47 In vitro translation was performed from a
plasmid carrying the full-length PDZK1 with the TNT T7 Quick for
polymerase chain reaction DNA system (Promega, Tokyo, Japan) in
the presence of Transcend Biotinylated tRNA (Promega), as
described elsewhere.29 Of in vitro-translated products, (5ml) was
applied into ProFoundTM Pull-Down GST Protein:Protein Interac-
tion Kit (Pierce, Rockford, IL, USA) with 50ml of GST-glutathione-
Sepharose resin and protein complexes were eluted according to the
manufacturer’s instructions.
Surface plasmon resonance
The interactions of PEPT2-CT with the second and third PDZ
domains of PDZK1 were investigated using a BIAcore 3000
analytical system (BIAcore AB, Tokyo, Japan). Using an amine
coupling kit, GST-fused wt PEPT2-CT or GST alone was attached to
a CM5 sensor chip according to the manufacturer’s instructions,
giving an increase of 11 214 resonance units (RU) for GST-PEPT2-
CT or 8,566 resonance units for GST alone. Binding experiments
were performed with the PDZK1 single PDZ domains fused with
maltose-binding protein as described elsewhere.29
Immunohistochemical analysis
We used human single-tissue slides (Biochain, Hayward, CA, USA)
for light microscopic immunohistochemical analysis as reported
previously.48 They were treated with 10 mg/ml primary rabbit
polyclonal antibodies against PEPT241 or PDZK1 (41C overnight).
Cell culture and transfection
HEK293 cells were maintained in Dulbecco’s-modified Eagle’s
medium supplemented with 10% fetal bovine serum, 1 mM sodium
pyruvate, penicillin (100 U/ml), and streptomycin (100 mg/ml)
(Invitrogen) at 371C in 5% CO2. Transient transfection with
Lipofectamine 2000 (Invitrogen, Gaithersburg, MD, USA) was
performed according to the manufacturer’s recommendations.
Immunoprecipitation and immunoblotting
Immunoprecipitation analysis was performed as described pre-
viously.49 Lysates from HEK293 cells that expressed GFP-fused
hPEPT2 and hPDZK1 were immunoprecipitated by the anti-GFP
antibody (full-length A.v. polyclonal antibody, Clontech). For the
co-immunoprecipitation of endogenous PEPT2 and PDZK1, we
used human kidney membrane fractions (Biochain) and added the
anti-PEPT2 antibody or control immunoglobulin G to this solution.
After overnight incubation, PEPT2 and PDZK1 were immunopre-
cipitated using the Seize Classic (A) Immunoprecipitation kit
(Pierce). The affinity-purified rabbit PDZK1 antibody and horse-
radish peroxidase-conjugated goat anti-rabbit immunoglobulin G
(Amersham Biosciences) were used for immunoblotting with
enhanced chemiluminescence reagents (ECL Plus, Amersham
Biosciences).
Gly-Sar transport activity assay
HEK293 cells were plated on 24-well culture plates at a density of
2 105 cells/well 24 h prior to transfection, and they were
transfected as described above. After 36 h, the culture medium was
removed, and the cells were washed three times and incubated in
Table 2 | PCR primers used in this study
Construct Sense primer Antisense primer
PEPT2-CTwt 50-CGAATTCCTGCCCGAGACCCAGAG-30 50-CTCTCGAGCTAAAACTGTGTGGATTTTA-30
PEPT2-CTd3 50-CGAATTCCTGCCCGAGACCCAGAG-30 50-CCCTCGAGCTAGGATTTTAGGACAGAGTTC-30
PEPT2-L727A 50-CGAATTCCTGCCCGAGACCCAGAG-30 50-CCCTCGAGCTAAGCCTGTGTGGATTTTAGGA-30
PEPT2-T729A 50-CGAATTCCTGCCCGAGACCCAGAG-30 50-CCCTCGAGCTAAAACTGTGCGGATTTTA-30
PCR, polymerase chain reaction; wt, wild type.
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serum-free Hank’s solution (containing in mM: 125 NaCl, 5.6
glucose, 4.8 KCl, 1. 2 MgSO4  7H2O, 1.2 KH2PO4, 1.3 CaCl2  2H2O,
25 N-2-hydroxyethylpiperazine-N0-2-ethanesulfonic acid (pH 6.0))
for 10 min. The uptake study was started by adding 500ml of
solution containing 30mM [14C]Gly-Sar to the plate. After 2 min, the
cells were washed twice in an ice-cold solution, and lysed in 0.1 N
NaOH for 20 min for scintillation counting.
To determine the kinetic parameters, the concentrations of Gly-
Sar were varied from 30 to 1000 mM. PEPT2-mediated Gly-Sar
uptake was calculated as the difference between the uptake rates into
HEK293 cells transiently expressing PEPT2 and those into HEK293
cells transfected with the vector (pcDNA3.1, Invitrogen) only.
Cell surface biotinylation
Surface biotinylation of PEPT2 at the plasma membrane was
performed as described elsewhere.49 Surface proteins in HEK293
cells transfected with pcDNA3.1(þ )-hPEPT2 and pcDNA3.1(þ )-
hPDZK1 or pcDNA3.1(þ ) empty vector (mock) were biotinylated
with Sulfo-NHS-SS-Biotin (Pierce) (0.5 mg/ml) in phosphate-
buffered saline for 30 min at 41C. Cell lysates were then incubated
with Ultralink-immobilized NeutrAvidin beads (Pierce) to precipi-
tate biotinylated proteins. PEPT2 was detected with polyclonal
PEPT2 antibody (1:10,000).41
Statistical analysis
Uptake experiments were conducted three times, and each uptake
experiment was performed in triplicate. Values are presented as the
mean7s.e. Statistical significance was determined by Student’s
t-test.
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